These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 10233630)

  • 21. Topical immunotherapy of severe alopecia areata with diphenylcyclopropenone (DPCP): experience in an Iranian population.
    Aghaei S
    BMC Dermatol; 2005 May; 5():6. PubMed ID: 15918897
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Treatment of alopecia areata with diphencyprone].
    Suditu G; Toma A; Voiculescu M
    Rev Med Chir Soc Med Nat Iasi; 2001; 105(4):760-2. PubMed ID: 12092234
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Topical immunotherapy with diphenylcyclopropenone-induced vitiligo.
    Kutlubay Z; Engin B; Songur A; Serdaroglu S; Tuzun Y
    J Cosmet Laser Ther; 2016 Aug; 18(4):245-6. PubMed ID: 26963903
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Diphencyprone is not detectable in serum or urine following topical application.
    Berth-Jones J; Mc Burney A; Hutchinson PE
    Acta Derm Venereol; 1994 Jul; 74(4):312-3. PubMed ID: 7976097
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of diphencyprone on expression of Bcl-2 protein in patients with alopecia areata.
    Pazoki-Toroudi H; Ajami M; Babakoohi S; Khaki L; Habibey R; Akhiani M; Seirafi H; Firooz A
    Immunopharmacol Immunotoxicol; 2010 Sep; 32(3):422-5. PubMed ID: 20095801
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and safety of diphenylcyclopropenone alone or in combination with anthralin in the treatment of chronic extensive alopecia areata: a retrospective case series.
    Durdu M; Özcan D; Baba M; Seçkin D
    J Am Acad Dermatol; 2015 Apr; 72(4):640-50. PubMed ID: 25653027
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Acquired hair curling after diphenylcyclopropenone immunotherapy in alopecia areata patient.
    Choe SJ; Kim BJ; Choi J; Lee WS
    J Eur Acad Dermatol Venereol; 2017 Aug; 31(8):e371-e372. PubMed ID: 28191673
    [No Abstract]   [Full Text] [Related]  

  • 28. Cytokine patterns in alopecia areata before and after topical immunotherapy.
    Happle R; Hoffmann R
    J Invest Dermatol; 1995 May; 104(5 Suppl):14S-15S. PubMed ID: 7537782
    [No Abstract]   [Full Text] [Related]  

  • 29. PTPN22 gene polymorphism in Egyptian alopecia areata patients and its impact on response to diphencyprone immunotherapy.
    El-Zawahry BM; Azzam OA; Zaki NS; Abdel-Raheem HM; Bassiouny DA; Khorshied MM
    Gene; 2013 Jul; 523(2):147-51. PubMed ID: 23570882
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Alopecia areata in children: response to treatment with diphencyprone.
    Hull SM; Pepall L; Cunliffe WJ
    Br J Dermatol; 1991 Aug; 125(2):164-8. PubMed ID: 1911299
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Randomized controlled study comparing the use of diphencyprone and anthralin in the treatment of extensive chronic alopecia areata.
    Rocha VB; Kakizaki P; Donati A; Machado CJ; Pires MC; Contin LA
    An Bras Dermatol; 2021; 96(3):372-376. PubMed ID: 33849753
    [No Abstract]   [Full Text] [Related]  

  • 32. Diphencyprone immunotherapy alters anti-hair follicle antibody status in patients with alopecia areata.
    Tobin DJ; Gardner SH; Lindsey NJ; Hoffmann R; Happle R; Freyschmidt-Paul P
    Eur J Dermatol; 2002; 12(4):327-34. PubMed ID: 12095876
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Topical immunotherapy changes the composition of the peribulbar infiltrate in alopecia areata.
    Happle R; Klein HM; Macher E
    Arch Dermatol Res; 1986; 278(3):214-8. PubMed ID: 2873796
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Diphencyprone and topical tacrolimus as two topical immunotherapeutic modalities. Are they effective in the treatment of alopecia areata among Egyptian patients? A study using CD4, CD8 and MHC II as markers.
    Hunter N; Shaker O; Marei N
    J Dermatolog Treat; 2011 Feb; 22(1):2-10. PubMed ID: 20524872
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Topical immunotherapy with diphenylcyclopropenone in patients with alopecia areata: A large retrospective study of 757 patients.
    Nasimi M; Abedini R; Ghandi N; Seirafi H; Mehdizade MS; Tootoonchi N
    Dermatol Ther; 2020 Nov; 33(6):e13808. PubMed ID: 32530566
    [No Abstract]   [Full Text] [Related]  

  • 36. Retrospective review of diphencyprone in the treatment of alopecia areata.
    Lamb RC; Young D; Holmes S
    Clin Exp Dermatol; 2016 Jun; 41(4):352-8. PubMed ID: 26620737
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Erythema Multiforme Major After Immunotherapy With Diphenylcyclopropenone for Alopecia Areata.
    Sanger J; Zahir A; Driscoll M; Gaspari AA
    Dermatitis; 2018; 29(6):348-349. PubMed ID: 30346328
    [No Abstract]   [Full Text] [Related]  

  • 38. Alopecia areata in a patient with candidiasis-endocrinopathy syndrome: unsuccessful treatment trial with diphenylcyclopropenone.
    Böni R; Trüeb RM; Wüthrich B
    Dermatology; 1995; 191(1):68-71. PubMed ID: 8589491
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Diphenylcyclopropenone immunotherapy in ophiasis.
    Singh G; Okade R; Naik C; Dayanand CD
    Indian J Dermatol Venereol Leprol; 2007; 73(6):432-3. PubMed ID: 18032873
    [No Abstract]   [Full Text] [Related]  

  • 40. [Alopecia areata and its treatment].
    Lammintausta K; Havu VK
    Duodecim; 1997; 113(17):1639-43. PubMed ID: 10650631
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.